RCE
RECCE LTD FPO [RCE]
Healthcare · ASX Small Cap
$0.5200 -3.7%
Updated 2026-03-02 · Scores refresh every scan
⚠ Funding Risk — Cash runway under 4 quarters. Capital raise or funding may be required.
Appeared in 2 consecutive scans→ Score +7First seen: 2026-02-25
Score Breakdown
Technical51
Catalyst53
Sentiment50
Fundamental20
Momentum62
Risk Gate50
Active Signals
Bullish Signals
- RSI oversold (potential bounce)
- Stochastic bullish crossover (from low)
- Price at lower Bollinger Band (oversold)
- Sustained volume spike (3.1x median) on DOWN trend
- Volatility contracting (breakout setup)
- Above 200-day MA (long-term uptrend)
- Low cash runway (2 quarters) - dilution risk
- 4C filed 2026-01-30
- Revenue in sharp decline (-79%)
- EPS estimates revised downward (-10pts)
- CANSLIM I: Institutional ownership (14%)
- Strong 12-1 momentum (+100%)
- ASX200 bullish (+1.5% 5d)
- RBA cutting (+2pts)
Risk Signals
- MACD momentum weakening
- Price below MAs (downtrend)
- Breakdown below 20-day support
- Negative 5-day momentum (-8.8%)
- Piotroski F-Score weak (3/9)
- Deeply negative margins (-285%)
- Insufficient sentiment data (defaulting to neutral)
- Neutral/mixed sentiment
- Revenue momentum declining (-79%)
Recent Catalysts
NONE Appendix 4D and Interim Financial Report
NONE Change of Director's Interest Notices (x5)
NONE Notification of cessation of securities - RCE
LOW Quarterly Activities/Appendix 4C Cash Flow Report
Announcement tone +3pts
Recent ASX Announcements
| 2026-02-27 | Appendix 4D and Interim Financial Report PRICE SENSITIVE |
| 2026-02-24 | Change of Director's Interest Notices (x5) |
| 2026-02-24 | Notification of cessation of securities - RCE |
| 2026-02-01 | Recce Enters Second U.S. Department of Defense R&D Agreement PRICE SENSITIVE |
| 2026-01-30 | Quarterly Activities/Appendix 4C Cash Flow Report PRICE SENSITIVE |
Key Metrics
$156.2M
Market Cap
59K
Avg Volume
3.1x
Vol Ratio
$0.28 — $0.73
52-Week Range
N/A
Short Interest
2 qtrs
Cash Runway
N/A
ROE
-285.4%
Profit Margin
CANSLIM Analysis
| Factor | Rating | Detail | |
|---|---|---|---|
| C | Current EPS | fail | EPS Growth: 0% |
| A | Annual Earnings | fail | CAGR: 0% |
| N | New Highs / Catalysts | neutral | |
| S | Supply & Demand | neutral | Float: 70% |
| L | Leader vs Laggard | laggard | RS: -3 |
| I | Institutional Sponsorship | pass | Inst: 14% |
| M | Market Direction | pass | Bullish |
Sector: Healthcare
Ranked #95 of 119 · Sector avg: 51
View all Healthcare signals →